Trial reportBiochemical and biophysical research communications2004
ACE1 polymorphism and progression of SARS.
Trial report in Biochemical and biophysical research communications, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05157217 (Impact of the Genetic Polymorphism on the Severity of COVID-19 Infection in Egyptian Patients), which is not on this map. Cited by 70 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of the Genetic Polymorphism on the Severity of COVID-19 Infection in Egyptian Patients
Who cites it
70 citing papers in PubMed, 6 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Relationship between Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and the Risk of COVID-19: A Meta-Analysis.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2023Pooled it
- Genetics of COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review.Annals of clinical and translational neurology · 2022Pooled it
- Genetic polymorphisms as multi-biomarkers in severe acute respiratory syndrome (SARS) by coronavirus infection: A systematic review of candidate gene association studies.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2021Pooled it
- Genetic variants of the human host influencing the coronavirus-associated phenotypes (SARS, MERS and COVID-19): rapid systematic review and field synopsis.Human genomics · 2020Pooled it
- Increased risk of pneumonia associated with angiotensin-converting enzyme (CD143) rs4340 polymorphism.Clinical and experimental medicine · 2016Pooled it
- Genetic Association Between CD143 rs4340 Polymorphism and Pneumonia risk: A Meta Analysis.Medicine · 2015Pooled it
- Systems genetics analysis reveals immune mediators of coronavirus disease severity in mice.Genetics · 2026Article
- The I/D variant of theFuture science OA · 2025Article
- The Distribution of Sport Performance Gene Variations Through COVID-19 Disease Severity.Diagnostics (Basel, Switzerland) · 2025Article
- Association of ACE1 I/D polymorphism and susceptibility to COVID-19 in Egyptian children and adolescents.Pediatric research · 2024Article
- The Relation between ACE Gene Polymorphism and the Severity of COVID-19 Infection.International journal of microbiology · 2023Article
- Analysis of Gene Single Nucleotide Polymorphisms in COVID-19 Disease Highlighting the Susceptibility and the Severity towards the Infection.Diagnostics (Basel, Switzerland) · 2022Article
- The COVID-19 Pandemic and Explaining Outcomes in Africa: Could Genomic Variation Add to the Debate?Omics : a journal of integrative biology · 2022Review
- Angiotensin-converting enzyme 1 and voltage-gated potassium channel-interacting protein 4 gene polymorphisms in COVID-19 patients from east of Iran.Clinica chimica acta; international journal of clinical chemistry · 2022Article
- Angiotensin-converting-enzyme insertion/deletion polymorphism, ACE activity, and COVID-19: A rather controversial hypothesis. A case-control study.Journal of medical virology · 2022Article
- Are angiotensin converting enzyme (ACE1/ACE2) gene variants associated with the clinical severity of COVID-19 pneumonia? A single-center cohort study.Anatolian journal of cardiology · 2022Article
- Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing.Ageing research reviews · 2022Review
- The role of angiotensin I converting enzyme insertion/deletion polymorphism in the severity and outcomes of COVID-19 patients.Frontiers in genetics · 2022Article
- p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics).Frontiers in pharmacology · 2022Review
- The Race for ACE: Targeting Angiotensin-Converting Enzymes (ACE) in SARS-CoV-2 Infection.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2022Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have hypothesized that genetic predisposition influences the progression of SARS. Angiotensin converting enzyme (ACE1) insertion/deletion (I/D) polymorphism was previously reported to show association with the adult respiratory distress syndrome, which is also thought to play a key role in damaging the lung tissues in SARS cases. This time, the polymorphism was genotyped in 44 Vietnamese SARS cases, with 103 healthy controls who had had a contact with the SARS patients and 50 controls without any contact history. SARS cases were divided into either non-hypoxemic or hypoxemic groups. Despite the small sample size, the frequency of the D allele was significantly higher in the hypoxemic group than in the non-hypoxemic group (p=0.013), whereas there was no significant difference between the SARS cases and controls, irrespective of a contact history. ACE1 might be one of the candidate genes that influence the progression of pneumonia in SARS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.